Reviewing Alexion Pharmaceuticals (ALXN) and Anika Therapeutics (ANIK)
Alexion Pharmaceuticals (NASDAQ: ALXN) and Anika Therapeutics (NASDAQ:ANIK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.
Institutional & Insider Ownership
94.2% of Alexion Pharmaceuticals shares are held by institutional investors. Comparatively, 84.5% of Anika Therapeutics shares are held by institutional investors. 4.4% of Alexion Pharmaceuticals shares are held by company insiders. Comparatively, 6.6% of Anika Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a breakdown of current recommendations and price targets for Alexion Pharmaceuticals and Anika Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Alexion Pharmaceuticals presently has a consensus price target of $158.41, suggesting a potential upside of 10.92%. Given Alexion Pharmaceuticals’ higher possible upside, equities research analysts plainly believe Alexion Pharmaceuticals is more favorable than Anika Therapeutics.
Risk and Volatility
Alexion Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.
This table compares Alexion Pharmaceuticals and Anika Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Alexion Pharmaceuticals and Anika Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Alexion Pharmaceuticals||$3.41 billion||9.35||$1.34 billion||$2.31||61.83|
|Anika Therapeutics||$111.36 million||7.46||$56.02 million||$2.26||25.08|
Alexion Pharmaceuticals has higher revenue and earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Alexion Pharmaceuticals beats Anika Therapeutics on 9 of the 14 factors compared between the two stocks.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.
About Anika Therapeutics
Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company’s therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company’s ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.